Benchling

🎉 Happy 1st birthday to !

In the last year, over 300 of our customers have taken part in our online community:
✔️ 1600+ members
✔️ 3500+ posts published
✔️ 395 product ideas submitted

🍻 Cheers to another inspiring year! Join us: https://community.benchling.com/?utm_campaign=organic&utm_source=facebook&utm_medium=social

☁️ Benchling is on the Forbes list for the 5th year in a row!

The union of software and biology is where the future unfolds — and we are honored to be part of it! 🧬⚡🧪

A heartfelt thank you to the 200,000+ scientists and 1,200+ companies worldwide who rely on Benchling to accelerate their breakthroughs.

Explore the full list: https://www.forbes.com/lists/cloud100

Discover how Neoplants is pioneering the future of plants. This French biotech is genetically engineering plants to metabolize common air pollutants. Their first product is already available, with more air-purifying plants on the way.

See how they’re using Benchling to scale their R&D with effective data management, robust data tracing, and improved visibility.

We’re proud to support their mission! 🌍🌱

https://www.benchling.com/blog/neoplants-scaling-sustainability?utm_campaign=organic&utm_source=facebook&utm_medium=social

Scaling sustainability at Neoplants: Planting the seeds for long-term growth Plants take in carbon dioxide and release oxygen — what if they could absorb things that are harmful to humans in our homes and offices? Read how Neoplants is bioengineering plants to purify air, and how Benchling helps power their growth.

What happens when over 1,500 scientists at Sanofi US transition from legacy systems to Benchling? Real-time visibility into standardized data across teams is a critical starting point for their ML models.

See how more than 30 global teams at Sanofi are accelerating R&D with Benchling — from early discovery-omics such as precision oncology, to core therapeutic pipeline teams including novel modalities like mRNA, and all the way up the lifecycle to translational teams.

https://www.benchling.com/customer-stories/benchling-builds-digital-data-foundation-powering-sanofi-ai-driven-r-and-d?utm_campaign=organic&utm_source=facebook&utm_medium=social

Benchling Builds Digital Data Foundation Powering Sanofi AI-Driven R&D 30+ global teams and 1,500 scientists at Sanofi use Benchling for scientific data, collaboration, and insights

What if billions of dollars in AI funding leads to the same number of new drugs? Today in STAT, Benchling’s co-founders weigh in on how to avoid over-promising and under-delivering on AI-driven drug discovery.

Could billions of dollars in AI funding lead to the same number of new drugs? We're entering an era of AI-driven drug discovery, which promises to be AI's greatest contribution by finding treatments for the thousands of currently untreatable diseases.

How is AI like self-driving cars? In Endpoints News, Benchling's CEO shares his prediction on the impact of AI in biotech.

What else does he talk about?
👉 How to get to 10x more science
👉 The convergence of tech and biotech
👉 The state of the biotech market

Read the full interview: https://endpts.com/the-endpoints-slack-interview-saji-wickramasekara-on-where-ai-misses-the-mark-and-whats-next-for-benchling/

Global pharma leader Sanofi US is paving the way for a new era of biotechnology, where every stage of R&D is faster, smarter, and more automated.

Benchling is proud to support 1,500+ scientists across 30 teams with a digital data foundation that enables Sanofi's AI-powered R&D.

https://www.benchling.com/news/benchling-builds-data-foundation-powering-sanofi-ai?utm_campaign=organic&utm_source=facebook&utm_medium=social

How are the most cutting-edge biotechnology companies using AI to supercharge R&D? Learn from Shape Therapeutics, where they're combining AI and RNA technology to generate hundreds of billions of therapeutic possibilities.

Read their story to learn how they’re:
✔️ Developing breakthroughs in programmable RNA
✔️ Paving the way for AI-enabled scientists and AI-ready data, with a 270% increase in use of pre-configured templates for data entries
✔️ Powering scale, automation, and last mile capabilities

https://www.benchling.com/customer-stories/shapetx-revolutionizing-the-field-of-gene-therapy-through-the-power-of-ai-or?utm_campaign=organic&utm_source=facebook&utm_medium=social

ShapeTx: Revolutionizing the field of gene therapy through the power of AI With Benchling as a central source of truth for R&D data, ShapeTX is developing innovative RNA-targeting technologies and advanced genetic medicines.

🎉 is officially here! Today we’re excited to deliver an end-to-end solution for modern, high-throughput process development.

Now with Bioprocess, scientists can:
⚡ Shorten development cycles
⚡ Simplify tech transfer
⚡ Enable -ready data

Find out how we’re accelerating R&D with additional product updates — from connecting more lab instruments to transforming your lab work with AI. https://www.benchling.com/whats-new?utm_campaign=organic&utm_source=facebook&utm_medium=social

🇩🇰 Denmark-based SNIPR Biome is tackling the global antimicrobial resistance crisis — with CRISPR-based therapeutics. Their microbial gene therapies precisely kill target bacteria, without affecting the rest of the microbiome.

SNIPR Biome started using Benchling nearly 5 years ago. Their first drug candidate is already in clinical trials, with more on the way.

Find out how they’re moving candidates through the pipeline faster with Benchling: https://www.benchling.com/customer-stories/snipr-biome-pioneering-crispr-based-microbial-gene-therapy-with-a-modern?utm_campaign=organic&utm_source=facebook&utm_medium=social

SNIPR Biome: Pioneering CRISPR-based microbial gene therapy with a modern, scalable R&D platform SNIPR Biome is bringing safe and effective CRISPR-based therapeutics to market faster through an efficient, standardized data foundation on the Benchling platform..

What did we build in 2023? Our biggest moments centered around key themes that came up again and again:

⚡ No more siloed data
⚡ Make FAIR happen
⚡ Purpose-built
⚡ Follow that molecule!
⚡ Improve life in the lab
⚡ AI. ML. AI. ML. AIMLAIMLAIML
⚡ Building community

See how these phrases guided some of our most exciting advancements yet:

Words we lived by in 2023: A year in review at Benchling Journey through 2023 with Benchling as we review our launches and biggest moments of the year.

Authera is a Norway-based biotech company focused on development and discovery of antibody-based therapeutics. They combine molecular and cellular understanding with a toolbox that allows them to validate and tailor molecules. Authera's innovative technology opens the door to totally new treatment possibilities.

We're excited to welcome Authera to the Benchling customer community!
https://www.authera.bio/.

Want to learn how to scale instrument connectivity? Or how to simplify tech transfer in process design?

Get your questions answered in our -focused webinar. You'll hear directly from the leaders and developers behind new Benchling products, and .

👉🏽 Takes place 21st of November, 10am GMT, sign-up here: https://www.benchling.com/webinars/whats-new-webinar-nov-2023-europe

Imagine a world where data is siloed and scientists can’t collaborate effectively and quickly to bring life-changing products to market. Now that’s scary! 👻 Happy Halloween, from Jeffy P(umpkin) to you! 🎃

Cell and gene therapies are revolutionizing the way we treat diseases — but bottlenecks in process development limit widespread patient access.

That’s where Ori Biotech comes in — empowering therapeutics developers to scale from pre-clinical process development to commercial-scale manufacturing.

Learn how their flexible platform:
Cuts experimental data capture and analysis time
Reduces data entry analysis errors
Cuts time taken to enter process data

Read the full story of how Ori Biotech is using Benchling to power a new generation of personalized, lifesaving treatments. https://www.benchling.com/customer-stories/ori-biotech

Mark your calendars for Benchling's upcoming "The Future of Antibody Drug Discovery: From Target Validation to Candidate Selection," webinar on September 28 at 10 am EST. Learn about:

🧠 The integration of software-led approaches, such as AI/ML, in antibody drug discovery is ushering in a new era of rapid and low-labor therapeutic development
👀 Learn about Benchling’s Antibody Solution Accelerator, a set of ready-to-use configurations necessary to capture the process of drug discovery from Benchling product experts Sanjay Saraf and Vega Shah.

Register today: https://ms.informaengage.com/AntibodyEngineeringandTherapeuticsDigitalWeek2023?PartnerRef=ISP-Benchling

Who else is excited for ? 🙌🏽 🙌 🙌🏽 🙌🏾

Here’s what’s in store for next week’s event:
🚀 New products unveiled
💡 Tech strategies for the new era of data + AI + biology with industry leaders
🤝 Community! Connect with peers, while enjoying great food, drinks, and swag 🍻

Check out the full schedule here: https://benchtalk.benchling.com/boston
For those of you missing out, don’t fret, we’ll be sharing recaps and product announcements.

UK biotech Etcembly is making groundbreaking strides in cancer research by using generative to develop a novel for challenging cancers. This is the first AI-generated immunotherapy candidate, and targets PRAME, a protein found in various cancers. Benchling is proud to serve Etcembly as they deliver powerful TCR immunotherapies through rapid computer-assisted engineering.

Generative AI Used to Develop T Cell Cancer Immunotherapy Etcembly has designed and created a new bispecific T cell engager therapy to target PRAME antigen presenting cancers using generative AI.

Explore the innovative software-led approaches revolutionizing antibody drug discovery in our newest blog highlighting some remarkable examples of how:

🖥️ Software Transforms Antibody Discovery: and are reshaping antibody drug development, replacing labor-intensive methods with faster processes.

🧬 Smart Design and Optimization: Software predicts interactions, binding sites, and antibody-antigen dynamics, yielding optimized variants with enhanced specificity.

🧪 Accelerated Screening with AI: Tools like AlphaFold predict protein structures, aiding virtual screening of antibody libraries. The integration of AI and ML promises rapid therapeutic development and transforming patients' treatment prospects.

The Power of Software-Led Antibody Drug Discovery | Benchling In this article, we explore the innovative software-led approaches revolutionizing antibody drug discovery, highlighting some remarkable examples of their application.